Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Trametinib
Related studies linked through entity extraction aliases.
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
- Status
- COMPLETED
- Phase
- PHASE3